Gerben van ‘t Klooster

Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases

Luc Van Rompaey, René Galien, Ellen M. van der Aar et al. · The Journal of Immunology · 2013 · 234 citations · Full text

Life Sciences, Immunology, Pharmacology +12

Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment

Lieven Baert, Gerben van ‘t Klooster, Willy Dries et al. · European Journal of Pharmaceutics and Biopharmaceutics · 2009 · 224 citations

Pharmacy, Pharmaceutics, Pharmacology +14

Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral Formulation

Gerben van ‘t Klooster, Eva Hoeben, Herman Borghys et al. · Antimicrobial Agents and Chemotherapy · 2010 · 186 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients

H. W. Reesink, Gregory Fanning, Khalid Abou Farha et al. · Gastroenterology · 2009 · 155 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +14

A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects

Aza Rakhmanova, Ekaterina Doubovskaya, A. A. Yakovlev et al. · AIDS · 2003 · 80 citations

Medicine, Pharmacology, Pharmacotherapy +13